Zimmerman Lani, Wilson Fernando A, Schmaderer Myra S, Struwe Leeza, Pozehl Bunny, Paulman Audrey, Bratzke Lisa C, Moore Kim, Raetz Libby, George Barb
1 University of Nebraska Medical Center, Omaha, NE, USA.
2 University of Wisconsin-Madison, Madison, WI, USA.
West J Nurs Res. 2017 May;39(5):622-642. doi: 10.1177/0193945916673834. Epub 2016 Oct 19.
The purpose of this pilot study was to assess the cost-effectiveness of four different doses (based on patients' level of cognition and activation) of a home-based care transitions intervention compared with usual care at 2 and 6 months after hospital discharge to home for 126 adult patients with three or more chronic diseases. Health care utilization was measured, and a cost-effectiveness analysis was used to estimate incremental costs and quality-adjusted life-years associated with each intervention arm. At 6 months, results from this pilot study are very promising and support cost-effectiveness for Group 2-low cognition/high activation, Group 3-normal cognition/low activation, and Group 4-normal cognition/high activation patients. However, Group 1-low cognition/low activation needs a more intensive treatment than what was provided in the intervention, because of their low cognition and activation levels. Our intervention strategies provided to the groups would be scalable to a larger patient population and across different facilities.
本试点研究的目的是评估针对126名患有三种或更多慢性病的成年患者,在出院回家后2个月和6个月时,与常规护理相比,四种不同剂量(基于患者的认知和激活水平)的居家护理过渡干预措施的成本效益。测量了医疗保健利用率,并采用成本效益分析来估计与每个干预组相关的增量成本和质量调整生命年。在6个月时,该试点研究的结果非常有前景,并支持第2组(低认知/高激活)、第3组(正常认知/低激活)和第4组(正常认知/高激活)患者的成本效益。然而,第1组(低认知/低激活)由于其低认知和激活水平,需要比干预中提供的更强化的治疗。我们提供给各小组的干预策略可扩展到更大的患者群体,并适用于不同的医疗机构。